Meningitis in neonates: bench to bedside.
The clinical outcome of central nervous system infection is determined by the characteristics of the pathogen and the brain's response to the invading bacteria. How infection leads to brain injury remains unresolved. An impediment to progress is the complexity of pathophysiologic processes. Some of the mechanisms involved have been identified in experimental models, providing insights into the molecular basis of brain injury and regeneration, and hinting at targets for therapy. Adjuvant therapies have been proposed. Interventions that protect the brain are evaluated for their potential to preserve neuro-integrative functions in long-term survivors of bacterial meningitis. This article summarizes current studies evaluating pharmacologic interventions in experimental models of bacterial meningitis and discusses how the knowledge gathered could translate into more effective therapies.
Grandgirard
Denis
D
Neuro-Infectiology Laboratory, Institute for Infectious Diseases, University of Bern, Friedbuehlstrasse 51, Bern 3010, Switzerland.
Leib
Stephen L
SL
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002490:Central Nervous System / Q000382:microbiology*; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D008586:Meningitis, Pneumococcal / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D011379:Prognosis; D013296:Streptococcus pneumoniae / Q000472:pathogenicity*
D000893:Anti-Inflammatory Agents